Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wuxi Biologics Inc. Appoints Ming Tu as Executive Vice President

08/24/2021 | 07:31pm EDT

The board of directors of WuXi Biologics (Cayman) Inc. announced that, with effect from August 23, 2021, Mr. Ming Tu ("Mr. Tu") has been appointed as Executive Vice President of the Group reporting to Ms. Christine Lu-Wong, the Chief Financial Officer and Executive Vice President of the Group. Mr. Tu will be primarily responsible for leading all aspects of the Company's financial strategy, performance, reporting and business planning, as well as functional support, such as treasury, tax, controllership and audit operations. Prior to joining the Group, Mr. Tu had served as the chief financial officer of General Electric ("GE") China and other senior management positions within GE group for around 24 years at different business units in China, the United States, Japan and other global locations. Since August 2019, he had served as the chief financial officer of the Home Credit China.


ę S&P Capital IQ 2021
All news about WUXI BIOLOGICS (CAYMAN) INC.
10/25Hong Kong shares close flat as gains in energy, materials offset realty losses
RE
10/25Shanghai stocks boosted by environmental protection firms; property stocks down
RE
10/18CHINA EVERGRANDE : Hong Kong shares close higher despite China's weak growth data
RE
10/08Hong Kong shares close 0.6% higher as tech and financial stocks gain
RE
10/08LI NING : China stocks rise on strong services data, easing Sino-U.S. tensions
RE
09/30SIHUAN PHARMACEUTICAL : Pharma, WuXi Bio Units to Collaborate on Breast Cancer Drug Candid..
MT
09/17Hong Kong shares rebound, led by tech, healthcare
RE
09/17Shanghai stocks fall as coal shares drag; Hong Kong rebounds
RE
09/14Hong Kong shares end lower, dragged by property, financials and tech
RE
09/06Hong Kong shares rise, led by tech and financials
RE
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2021 9 538 M 1 495 M 1 495 M
Net income 2021 2 971 M 465 M 465 M
Net cash 2021 5 831 M 914 M 914 M
P/E ratio 2021 168x
Yield 2021 -
Capitalization 509 B 65 479 M 79 777 M
EV / Sales 2021 52,8x
EV / Sales 2022 35,7x
Nbr of Employees 7 686
Free-Float 84,4%
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 120,00 CNY
Average target price 129,59 CNY
Spread / Average Target 7,99%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Chief Executive Officer & Executive Director
Shao Hua Lu-Wong Co-Chief Financial Officer
Ming Tu Co-Chief Financial Officer & Executive VP
Ge Li Non-Executive Chairman
Weichang Zhou Executive Director, Chief Technology Officer & EVP
Sector and Competitors